Physician profile
Vikramaditya Dulam
NPI 1194767806
$2,771.28
in general payments reported to CMS, 2019-2025
15 companies · $592 in 2025
The $592 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $532 · 2021: $639 · 2022: $460 · 2023: $308 · 2024: $100 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $503.44 | 2025 | Artix Mt, Flowtriever, Venacore Thrombectomy Catheter |
| Merck Sharp & Dohme LLC | $475.97 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $422.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.64 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $249.44 | 2020-2023 | Brilinta |
| Novartis Pharmaceuticals Corporation | $231.29 | 2019-2022 | |
| Pfizer INC. | $184.21 | 2019-2024 | |
| Abbott Laboratories | $124.53 | 2020-2022 | |
| Scpharmaceuticals INC. | $52.50 | 2024-2025 | |
| Philips North America LLC | $32.29 | 2025 | Lm Undivided |
| Amgen INC. | $31.75 | 2021-2023 | Repatha |
| Biotronik INC. | $24.18 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.23 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.47 | 2023 | Inpefa |
| Medtronic, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikramaditya Dulam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.